Comparison of irinotecan/carboplatin versus etoposide/carboplatin for extended disease small cell lung cancer (ED‐SCLC): A systematic review and meta‐analysis of randomized controlled trials
Malignancy Spectrum · 2024
DOI: 10.1002/msp2.46 ↗At a glance
Systematische Übersicht in Malignancy Spectrum, 2024. Written by Zeeshan Afzal and 3 co-authors. 26 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Background
Platinum‐based chemotherapy in addition to the non‐platinum agent etoposide is the standard of care for extensive‐stage small cell lung cancer (ES‐SCLC). However, the front‐line chemotherapy regimen is not known. Therefore, we aimed to perform this review comparing irinotecan/carboplatin (IC) and etoposide/carboplatin (EC) in patients of extended disease small cell lung cancer (ED‐SCLC).
Methods
We searched three databases, that is, PubMed, Embase, and Cochrane Library. The outcomes for complete response (CR), median overall survival (OS), and progression‐free survival (PFS) were evaluated. In addition, adverse events such as leukopenia, thrombocytopenia, anemia, diarrhea, and infections were also assessed. RevMan 5.4.1 was used to perform the statistical analysis.
Results
Three randomized controlled trials (RCTs) with 676 patients were included. There was a significant difference between IC and EC arms in terms of CR (risk ratio [RR] = 2.52; 95% confidence interval [CI]: 1.20−5.32; p = 0.02, I 2 (i.e., the percentage of the total variance that is due to between‐study heterogeneity) = 0%), leukopenia (RR = 0.47; 95% CI: 0.23−0.97; p = 0.04; I 2 = 90%), amimia (RR = 0.55; 95% CI: 0.38−0.78; p = 0.0008; I 2 = 0%), thrombocytopenia (RR = 0.51; 95% CI: 0.39–0.68; p = 0.00001; I 2 = 0%), and diarrhea (RR = 4.88; 95% CI: 1.64−14.49; p = 0.004; I 2 = 33%). There was no statistically significant difference between IC and EC arms in terms of median OS (hazard ratio [HR] = 1.16; 95% CI: 0.84−1.62; p = 0.37; I 2 = 74%), PFS (HR = 1.04; 95% CI: 0.69−1.56; p = 0.85; I 2 = 77%), nausea (RR = 1.70; 95% CI: 0.76−3.81; p = 0.19; I 2 = 0%), infection (RR = 0.97; 95% CI: 0.64−1.48; p = 0.89; I 2 = 0%), and treatment‐related deaths (RR = 0.58; 95% CI: 0.24−1.42; p = 0.23; I 2 = 0%).
Conclusion
This meta‐analysis provides valuable evidence supporting the superiority of IC regimens over EC regimens in terms of CR and toxicity profile for ED‐SCLC.
Cite
APA
Afzal, Z., Hira, S., Song, X., & Wang, N. (2024). Comparison of irinotecan/carboplatin versus etoposide/carboplatin for extended disease small cell lung cancer (ED‐SCLC): A systematic review and meta‐analysis of randomized controlled trials. Malignancy Spectrum. https://doi.org/10.1002/msp2.46
Vancouver
Afzal Z, Hira S, Song X, Wang N. Comparison of irinotecan/carboplatin versus etoposide/carboplatin for extended disease small cell lung cancer (ED‐SCLC): A systematic review and meta‐analysis of randomized controlled trials. Malignancy Spectrum. 2024. doi:10.1002/msp2.46
BibTeX
@article{Afzal2024,
author = {Afzal, Zeeshan and Hira, Sara and Song, Xia and Wang, Na},
title = {Comparison of irinotecan/carboplatin versus etoposide/carboplatin for extended disease small cell lung cancer (ED‐SCLC): A systematic review and meta‐analysis of randomized controlled trials},
journal = {Malignancy Spectrum},
year = {2024},
doi = {10.1002/msp2.46}
}
EUVIMED